Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC ≥ 1+), non-breast/non-gastri...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Discov
Main Authors: Tsurutani, Junji, Iwata, Hiroji, Krop, Ian, Jänne, Pasi A., Doi, Toshihiko, Takahashi, Shunji, Park, Haeseong, Redfern, Charles, Tamura, Kenji, Wise-Draper, Trisha M., Saito, Kaku, Sugihara, Masahiro, Singh, Jasmeet, Jikoh, Takahiro, Gallant, Gilles, Li, Bob T.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8292921/
https://ncbi.nlm.nih.gov/pubmed/32213540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-1014
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares